Home › Soft Tissue Sarcoma › Pennsylvania
Soft Tissue Sarcoma clinical trials in Pennsylvania
15 studies for Soft Tissue Sarcoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Nov 5, 2026 · NCT05734066Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05711615Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- IRMC Cancer Center, Indiana
- and 6 more
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients
- Children's Hospital of Philadelphia, Phildelphia
RecruitingEarly phase 1
Ages 12 to 17 · All sexes · Updated Nov 2, 2026 · NCT07658768Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Oct 28, 2026 · NCT06710756A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610DESTINY-PANTUMOUR04
- Research Site, Philadelphia
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia
- University of Pennsylvania Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
- Children's Hospital of Philadelphia, Philadelphia
- University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 5 to 40 · All sexes · Updated Sep 3, 2026 · NCT06156410A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
- Temple University - Fox Chase Cancer Center, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06263231Synovial Sarcoma Registry / Biospecimen Repository
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Jun 9, 2026 · NCT05910307Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
- Thomas Jefferson University Hospital, Philadelphia
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT07436364Fluorescent Intra-operative Tumor Margin Examination
- UPMC-Shadyside Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Feb 20, 2026 · NCT04719156A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2025 · NCT04370587Genomic Risk in Retroperitoneal Sarcoma
- Fox Chase Cancer Center, Philadelphia
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 31, 2024 · NCT06436846From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.